Endothelin antagonism prevents diabetic retinopathy in NOD mice: A potential role of the angiogenic factor adrenomedullin

Experimental Biology and Medicine

Volumn 231, Issue 6, 2006, Pages 1101-1105

  Shaw, Sidney G ^a   Boden, Jane P ^a   Biecker, Erwin ^a   Reichen, Juerg ^a   Rothen, Barbara ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Adrenomedullin; Diabetes; Endothelin 1; Retinopathy

Indexed keywords

ADRENOMEDULLIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; LU 208075; NEURONAL NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DIABETIC RETINOPATHY; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADRENOMEDULLIN; ANIMALS; BLOOD GLUCOSE; DIABETIC RETINOPATHY; ENDOTHELIN-1; FEMALE; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MICE; MICE, INBRED NOD; PEPTIDES; PHENYLPROPIONATES; RECEPTOR, ENDOTHELIN A; TIME FACTORS; VASODILATOR AGENTS;

ANIMALIA;

EID: 33744904449     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, van den Enden M, Kilo C, Tilton RG. Perspectives in diabetes: hyperglycemic pseudohypoxia and diabetic complications. Diabetes 46:S19-S25, 1993.
2. Cohen RA. Endothelial dysfunction in diabetic vascular disease. Mediographia 19:157-161, 1997.
3. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LE, King GL. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective betaisoform-selective inhibitor. Diabetes 46:1473-1480, 1997.
4. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New Eng J Med 331:1480-1487, 1994.
5. Ceriello A, Dello Russo P, Zuccotti C, Florio A, Nazzaro S, Pietrantuono C, Rosata GB. Decreased antithrombin III activity in diabetes may be due to non-enzymatic glycosylation: a preliminary report. Thromb Haemost 50:633-634, 1983.
6. Miyamoto K, Hiroshiba N, Tsujikawa A, Ogura Y. In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Opthalmol Vis Sci 39:2190-2194, 1998.
7. Pedram A, Razandi M, Hu RM, Lavin ER. Vasoactive peptides modulate vascular endothelial growth factor production and endothelial cell proliferation and invasion. J Biol Chem 27:17,097-17,103, 1997.
8. Lam HC, Lee JK, Lu CC, Chu CH, Chuang MJ, Wang MC. Role of endothelin in diabetic retinopathy. Curr Vasc Pharmacol 3:243-250, 2003.
9. Chakrabarti S, Sima AAF. Endothelin-1 and endothelin-3 like immunoreactivity in the eyes of diabetic and non-diabetic BB/W rats. Diabetes Res Clin Pract 37:109-120, 1997.
10. Hopfner RI, Gopalakrishnan V. Endothelin: emerging role in diabetic vascular complications. Diabetologia 42:1383-1394, 1999.
11. Tagaki C, Bursell SE, Lin YW, Takagi H, Duh E, Jiang Z, Clermont AC, King GL. Regulation of retinal hemodynamics in diabetic rats by increased expression and action of endothelin-1. Invest Opthalmol Vis Sci 37:2504-2518, 1998.
12. Deng DX, Evans T, Mukherjee K, Downey D, Chakrabarti S. Diabetes induced dysfunction in the retina: role of endothelins. Diabetologia 42: 1228-1234, 1999.
13. Tilton RG, Chang K, Hasan KS, Smith SR, Petrash JM, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML. Prevention of diabetic dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42:221-232, 1993.
14. Ito S, Fujisawa K, Sakamoto T, Ishibashi T. Elevated adrenomedullin in the vitreous of patients with diabetic retinopathy. Opthalmologica 217:53-57, 2003.
15. Huang W, Wang L, Yuan M, Ma JX, Hui YN. Expression of adrenomedullin receptor in the epiretinal membranes of proliferative vitreoretinopathy. Zhonghua Yan Ke Za Zhi 40:317-320, 2004.
16. Kato J, Tsuruda T, Kita T, Kitamura K, Eto T. Adrenomedullin. A protective factor for blood vessels. Arterioscl Thromb Vasc Biol 25: 2480-2487, 2005.
17. Cormier-Regard S, Nguyen SV, Claycomb WC. Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiomyocytes. J Biol Chem 273:17,787-17,792, 1998.
18. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-oncol 7:134-153, 2005.
19. Nagava N, Mori H, Murakami S, Kangawa K, Kitamura S. Adrenomedullin: angiogenesis and gene therapy. Am J Physiol Regul Integr Comp Physiol 288:R1432-R1437, 2005.
20. Ribatti D, Nico B, Spinazzi R, Vacca A, Nussdorfer GG. The role of adrenomedullin in angiogenesis. Peptides 26:1670-1675, 2005.
21. Noda K, Ishida S, Inoue M, Obata K, Oguchi Y, Okada Y, Ikeda E. Production and activation of matrix metalloprotease-2 in proliferative diabetic retinopathy. Invest Opthalmol Vis Sci 44:2163-2170, 2003.
22. Martinez A, Oh HR, Unsworth FJ, Bregonzio C, Saavedra JM, Stetler-Stevenson WG, Cuttitta F. Matrix metalloprotease-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J 383: 413-418, 2004.